8-K

Date: September 8, 2026

/s/ Michele Greco

Michele Greco

Chief Financial Officer and

Chief Administrative Officer

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 8, 2026

VERU INC.

(Exact name of registrant as specified in its charter)


Wisconsin	1-13602	39-1144397
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2916 N. Miami Avenue, Suite 1000, Miami, Florida 33127

Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (305) 509-6897

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value per share	VERU	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01

Other Events.

On September 8, 2026, Veru Inc. issued a press release (“Press Release”) announcing that based on new, positive preclinical data for its oral, novel, microtubule targeting agent, sabizabulin, demonstrating augmented anticancer activity in KRAS-metastatic pancreatic cancer cell lines that were resistant to daraxonrasib (RASONQUE^™^*Revolution Medicines), and previous preclinical and clinical sabizabulin studies, the Company has made the strategic decision to expand its current drug development pipeline to advance sabizabulin as a potential novel treatment for patients whose metastatic pancreatic cancer has become resistant to daraxonrasib. Consequently, the Company will no longer be exploring sabizabulin for the treatment of chronic inflammation related to atherosclerotic cardiovascular disease. A copy of the Press Release is attached as Exhibit 99.1 to this report and incorporated by reference herein.

^* RASONQUE^™ is a trademark of Revolution Medicines, Inc.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.		Document

99.1		Press Release of Veru Inc., issued September 8, 2026.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.